Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Comacadine** is GrowLab Pharmaceuticals' proprietary, orally administered full-spectrum cannabis-extract formulation derived from its DNA-specific medical-cannabis strains. The company describes the product as containing cannabidiol, tetrahydrocannabinol, terpenes, and other cannabis-derived constituents, and supplies it as liquid and capsule products. GrowLab has publicly claimed clinical development and therapeutic use in diabetes mellitus, glaucoma, arthritis, and hypertension; however, the reviewed public materials do not specify a regulatory approval, a registered trial identifier, a controlled-study design, or a formal clinical-development phase. ([growlabplc.com](https://growlabplc.com/comacadine/))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Comacadine.